AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Akari Therapeutics PLC (NASDAQ:AKTX)
10.94 USD
-1.060 8.833%Sponsored Reports
Loading...
| Previous Close (in USD) | 12 |
|---|---|
| Change | -1.060 8.833% |
| 52 W H/L (in USD) | 59.600/3.250 |
| EBITDA (in USD) | -12.081M |
| PE Ratio | -- |
| Volume | 67632 |
| Diluted Eps TTM | -- |
| Total Assets (in USD) | 47.892M |
|---|---|
| Total Liabilities (in USD) | 19.564M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 5.203M |
| Market Cap (in USD) | 6.799 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Employees: 5
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Ray Prudo-Chlebosz M.D. | Exec. Chairman | 1945 |
| 2. | Dr. Torsten Hombeck | Chief Financial Officer | 1970 |
| 3. | Ms. Rachelle Suzanne Jacques | Pres, CEO & Director | 1971 |
| 4. | Ms. Melissa Bradford-Klug | Chief Operating Officer | NA |
| 5. | Dr. Miles Nunn | Chief Scientific Officer | NA |
| 6. | Dr. John F. Neylan III, M.D. | Exec. VP & Chief Medical Officer | 1953 |
| 7. | Annie Mack | Financial Controller | NA |
| 8. | Ms. Rachelle Suzanne Jacques | President, CEO & Director | 1971 |
| 9. | Ms. Wendy F. DiCicco CPA | Interim Chief Financial Officer | 1967 |
| 10. | Ms. Melissa Bradford-Klug | Chief Operating Officer | 1970 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.330 0.758% | 43.45 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 43 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.360 1.604% | 462.17 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.010 0.331% | 612.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -18.301M | -19.791M | -10.008M | -17.748M | -17.424M |
| Minority Interest | - | - | - | - | - |
| Net Income | -17.298M | -19.791M | -10.008M | -6.972M | -17.607M |
| Selling General Administrative | 9.28M | 9.664M | 11.356M | 13.527M | 8.081M |
| Gross Profit | - | -0.014M | -0.004M | - | - |
| Reconciled Depreciation | 0M | 0.014M | 0.004M | 0.004M | 0.004M |
| Ebit | - | -19.547M | -16.806M | -23.088M | -17.214M |
| Ebitda | -17.275M | -19.533M | -16.802M | -28.52M | -17.017M |
| Depreciation And Amortization | - | 0.014M | 0.004M | -5.432M | 0.197M |
| Operating Income | -17.275M | -21.643M | -16.806M | -23.088M | -17.214M |
| Other Operating Expenses | 17.275M | 21.643M | 16.806M | 23.088M | 17.214M |
| Interest Expense | 0.949M | 0.244M | 0M | -5.34M | 0.21M |
| Tax Provision | -1.003M | 0M | - | -2.472M | - |
| Interest Income | 0.001M | 0.008M | 0.082M | 0.046M | 0.011M |
| Net Interest Income | -0.948M | -0.236M | 0.082M | 0.046M | 0.011M |
| Income Tax Expense | -1.003M | - | - | -10.776M | 0.183M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 17.275M | 21.643M | 16.806M | 23.891M | 17.214M |
| Cost Of Revenue | - | 0.014M | 0.004M | - | - |
| Total Other Income Expense Net | -1.026M | 1.852M | 6.798M | 5.34M | -0.21M |
| Net Income From Continuing Ops | -17.298M | -19.791M | -10.008M | -17.748M | -17.424M |
| Net Income Applicable To Common Shares | - | - | - | - | -17.424M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 47.892M | 50.562M | 4.355M | 13.832M | 11.648M |
| Intangible Assets | 34M | 39.18M | 0.014M | 0.017M | 0.023M |
| Other Current Assets | 0.259M | 0.152M | 0.496M | 0.1M | 0.09M |
| Total Liab | 19.564M | 28.333M | 4.584M | 12.041M | 6.093M |
| Total Stockholder Equity | 28.328M | 22.229M | -0.229M | 1.791M | 5.555M |
| Other Current Liab | 2.827M | 4.243M | 2.913M | 11.094M | 4.305M |
| Common Stock | - | 5.319M | 1.324M | 0.744M | 0.476M |
| Capital Stock | 0M | 5.319M | - | 0.744M | 0.476M |
| Retained Earnings | -264.55M | -247.252M | -227.461M | -217.453M | -199.705M |
| Good Will | 8.43M | 8.43M | - | - | - |
| Other Assets | - | - | - | - | - |
| Cash | 5.203M | 2.599M | 3.845M | 13.25M | 9.361M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 12.351M | 19.91M | 4.584M | 12.041M | 6.093M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -4.449M | 0.661M | -3.845M | -13.25M | -9.361M |
| Short Term Debt | 0.754M | 3.26M | - | - | - |
| Short Long Term Debt | 0.754M | 3.26M | - | - | - |
| Short Long Term Debt Total | 0.754M | 3.26M | - | - | - |
| Other Stockholder Equity | 293.66M | 264.9M | 174.754M | 219.27M | 205.325M |
| Property Plant Equipment | - | - | - | - | - |
| Total Current Assets | 5.462M | 2.952M | 4.341M | 13.815M | 11.625M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | - | 0.201M | - | 2.951M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | -2.486M | - |
| Accounts Payable | 8.77M | 12.407M | 1.671M | 0.947M | 1.789M |
| Accumulated Other Comprehensive Income | -0.782M | -0.738M | 51.154M | -0.771M | -0.541M |
| Non Currrent Assets Other | - | - | 0.014M | - | - |
| Non Current Assets Total | 42.43M | 47.61M | 0.014M | 0.017M | 0.023M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | 0.382M | 0M | - | - |
| Total Cashflows From Investing Activities | - | 0.382M | - | - | - |
| Total Cash From Financing Activities | 13.171M | 10.988M | 7.02M | 25.288M | 14.293M |
| Net Income | -17.298M | -19.791M | -10.008M | -17.748M | -17.424M |
| Change In Cash | 2.604M | -1.186M | -9.405M | 3.889M | -4.695M |
| Begin Period Cash Flow | 2.659M | 3.845M | 13.25M | 9.361M | 14.056M |
| End Period Cash Flow | 5.263M | 2.659M | 3.845M | 13.25M | 9.361M |
| Total Cash From Operating Activities | -10.568M | -12.552M | -16.432M | -21.505M | -18.847M |
| Depreciation | 0M | 0.014M | 0.004M | 0.004M | 0.004M |
| Other Cashflows From Investing Activities | - | 0.382M | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | 13.171M | 0.028M | 0.004M | 0.094M | - |
| Capital Expenditures | 0M | 0M | 0M | 0M | 0M |
| Change In Working Capital | -0.404M | 6.539M | -0.866M | 0.822M | -1.984M |
| Other Non Cash Items | 5.332M | -1.559M | -6.712M | -5.317M | 0.243M |
| Free Cash Flow | -10.568M | -12.552M | -16.432M | -21.505M | -18.847M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RiverNorth Marketplace Lending Corp | 5 months ago | 1103 |
| 2. | RiverNorth Opportunities | 5 months ago | 509 |
| 3. | LUX IM Global Medtech HX | 2 months ago | 64 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Armistice Capital, LLC | 5 months ago | 2723966 |
| 2. | Cresset Asset Management, LLC | 5 months ago | 822468 |
| 3. | Warberg Asset Management LLC | 5 months ago | 308340 |
| 4. | Palo Alto Investors, LLC | 5 months ago | 146024 |
| 5. | HighTower Advisors, LLC | 5 months ago | 79236 |
| 6. | Jane Street Group LLC | 5 months ago | 71644 |
| 7. | SmartHarvest Portfolios, LLC | 5 months ago | 69248 |
| 8. | CWA Asset Management Group, LLC | 5 months ago | 55000 |
| 9. | XTX Topco Ltd | 5 months ago | 49019 |
| 10. | HPM Partners LLC | 5 months ago | 23643 |
| 11. | Virtu Financial LLC | 8 months ago | 22502 |
| 12. | Skyview Financial Group LLC | 5 months ago | 20575 |
| 13. | Independent Advisor Alliance | 5 months ago | 17075 |
| 14. | Goss Wealth Management LLC | 5 months ago | 6800 |
| 15. | Accent Capital Management LLC | 5 months ago | 5000 |
| 16. | SBI Securities Co Ltd | 5 months ago | 200 |
| 17. | Bank of America Corp | 8 months ago | 150 |
| 18. | UBS Group AG | 8 months ago | 60 |
| 19. | Truvestments Capital LLC | 5 months ago | 50 |
| 20. | Cornerstone Planning Group LLC | 5 months ago | 5 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...